A review of ropinirole prolonged release in Parkinson’s disease

Figures & data

Table 1 Available pharmacological treatment options for Parkinson’s disease

Pharmacological treatments for Parkinson’s disease
Dopamine precursor
Carbidopa/levodopa (Sinemet^®, Parcopa^®, generics)
Carbidopa/levodopa extended release (Sinemet CR^®, generics)
Dopamine agonists
Ropinirole (Requip^®, generic)
Ropinirole prolonged release (Requip XL^®)
Pramipexole (Mirapex^®)
Rotigotine patch (Neupro^®)
Apomorphine injections (Apokyn^®)
MAO-B inhibitors
Rasagiline (Azilect^®)
Selegiline (Eldepryl^®)
Orally disintegrating selegiline (Zelapar^®)
COMT inhibitors
Entacapone (Comtan^®)
Carbidopa/levodopa/entacapone (Stalevo^®)
Tolcapone (Tasmar^®)
Anticholinergics
Benztropine (Cogentin^®)
Trihexyphenidyl (Artane^®)
Antiglutamatergics
Amantadine (Symmetrel^®)

Abbreviations: COMT, catechol-O-methyltransferase; MAO-B, monoamine oxidase type B.

Table 2 Conversion from ropinirole immediate release to ropinirole prolonged release²⁹

Ropinirole immediate release total daily dose (mg)	Ropinirole prolonged release daily dose (mg)
0.75–2.25	2
3–4.5	4
6	6
7.5–9	8
12	12
15–18	16
21	20
24	24

Requip XL (ropinirole extended release tablets): US Prescribing Information: GlaxoSmithKline2008

 Google Scholar